Should their doctors agree, breast cancer patients with scleroderma may undergo radiation therapy — despite research suggesting it increases the…
Iqra Mumal, MSc
Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Iqra Mumal, MSc
The first clinical symptom at onset, also called the mode of onset, should be considered a prognostic factor in patients…
Systemic sclerosis affects quality of life and places a financial burden on the healthcare system, a study indicates. The research,…
Male gender and certain lung function parameters are potential risk factors for the progression of pulmonary arterial hypertension in patients with systemic sclerosis-PAH…
Nintedanib Reduces Fibrosis and Blood Vessel Remodeling in Mice with Systemic Sclerosis, Study Shows
Nintedanib alleviated the core manifestations of systemic sclerosis, resulting in a marked improvement in the disease, a study in mice…
World Health Organization Grants Name ‘Lanifibranor’ to Inventiva’s IVA337 to Treat SSc, NASH
Inventiva Pharma, which develops therapies for fibrotic diseases, said the World Health Organization (WHO) has granted the International Non-Proprietary…
The prevalence of autoantibodies, particularly Anti-Topo I, anti-CENP, and anti-RNA pol III, in patients with systemic sclerosis (SSc) can aid…